The Effect of Losartan in Bicuspid Aortic Valve Patients
The Effect of Losartan Treatment on Matrix Metalloproteinase Levels and Outcomes in Bicuspid Aortic Valve Patients
Sponsor: University of Michigan
Terminated
Due to low enrollment the decision was made to terminate study prior to final data collection for any individual.
Listed as NCT01390181, this NA trial focuses on Bicuspid Aortic Valve and Thoracic Aortic Aneurysm and remains terminated or withdrawn. Sponsored by University of Michigan, it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2024 [monthly]
Terminated NA
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Nov 2020 — Jan 2021 [monthly]
Terminated NA
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated NA
-
May 2018 — Jun 2018 [monthly]
Terminated NA
-
Aug 2017 — May 2018 [monthly]
Terminated NA
-
May 2017 — Aug 2017 [monthly]
Terminated NA
Status: Unknown Status → Terminated
-
Jan 2017 — May 2017 [monthly]
Unknown Status NA
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Michigan
For direct contact, visit the study record on ClinicalTrials.gov .